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ABSTRACT 
Objective. – A number of observations have suggested that brain derived neurotrophic factor (BDNF) 
plays a role in migraine pathophysiology. This study investigates whether variants in the BDNF gene 
are associated with migraine in an Australian case-control population. 
Background. – Brain derived neurotrophic factor (BDNF) has an important role in neural growth, 
development and survival in the central nervous system and is an important modulator of central and 
peripheral pain responses. Variants in BDNF, in particular the functional Val66Met polymorphism 
(rs6265), have been found to be associated with a number of psychiatric disorders, cognitive function 
and obesity. As BDNF has been found to be differentially expressed in a number of aspects related to 
migraine, we tested for association between single nucleotide polymorphisms (SNPs) in BDNF and 
migraine. 
Methods. – Five SNPs in the BDNF locus (rs1519480, rs6265, rs712507, rs2049046 and rs12273363) 
were genotyped initially in a cohort of 277 migraine cases, including 172 diagnosed with migraine with 
aura (MA) and 105 with migraine without aura (MO), and 277 age- and sex-matched controls. Three 
of these SNPs (rs6265, rs2049046 and rs12273363) were subsequently genotyped in a second cohort 
of 580 migraineurs, including 473 diagnosed with MA and 105 with MO, and 580 matched controls.  
Results. – BDNF SNPs rs1519480, rs6265, rs712507 and rs12273363 were not significantly associated 
with migraine. However, rs2049046 showed a significant association with migraine, and in particular, 
MA in the first cohort. In the second cohort, although an increase in the rs2049046 T-allele frequency 
was observed in migraine cases, and in both MA and MO subgroups, it was not significantly different 
from controls. Analysis of data combined from both cohorts for rs2049046 showed significant 
differences in the genotypic and allelic distributions for this marker in both migraine and the MA sub-
group.  
Conclusion. – This study confirmed previous studies that the functional BDNF SNP rs6265 (Val66Met) 
is not associated with migraine. However, we found that rs2049046, which resides at the 5’ end of 
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one the BDNF transcripts, may be associated with migraine, suggesting that further investigations of 
this SNP may be warranted. 
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INTRODUCTION 
 
Migraine is a common episodic neurological disorder characterized by severe head pain, usually 
accompanied by nausea, vomiting, neurological disturbance, photophobia and phonophobia. 
Migraine affects approximately 6% of men and 17% of women and has significant personal, social and 
economic burdens [1]. Two main types of migraine have been classified by the International Headache 
Society [IHS], migraine with aura (MA) or without aura (MO) [2]. MA is distinguished by the presence 
of neurological disturbances preceding headache in the early stages of the attack. These are usually 
visual, taking the form of scintillating shapes, hallucinations or black spots. The pathophysiology of 
migraine is only partially understood, but is believed to be caused by activation of the 
trigeminovascular system which results in vasodilation of pain-producing intracranial blood vessels 
and activation of second-order sensory neurons in the trigeminal nucleus caudalis with subsequent 
perception of pain [3].  
 
Brain derived neurotrophic factor (BDNF) has an important role in neuronal growth, developmental 
and survival in the central nervous system (CNS) [4], and has also emerged as an important modulator 
of central and peripheral nociceptor responses [5, 6]. The BDNF gene is complex; it contains 11 exons 
that are alternatively spliced to encode many transcripts which are differentially expressed in diverse 
tissues, and in various regions within the brain, including high expression in the CNS, including the 
trigeminal ganglion neurons (TGNs) [7]. BDNF is synthesized as a precursor protein (proBDNF) that is 
proteolytically cleaved to produce mature BDNF [8]. ProBDNF preferentially binds the receptor 
p75NTR which can trigger apoptosis, axonal retraction and pruning dendritic spines and mature BDNF 
binds the TrkB receptor tyrosine kinase which affects cell cycle, neurite outgrowth and synaptic 
plasticity [9]. Decreased BDNF in serum is one of the best known biological markers of depression and 
other psychiatric disorders [10, 11].  
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A number of observations have suggested that BDNF may also play a role in migraine. Studies have 
shown that serum levels of BDNF are elevated both during a migraine attack [12], and when compared 
to non-migraineur controls [13]. Migraineurs have also been found to have a significant decrease in 
levels of BDNF in platelets compared to controls [14], possibly attributable to platelet activation during 
migraine attacks with immediate release of BDNF [13]. BDNF is a mediator of activity-dependent 
plastic changes in second-order trigeminal neurons that characterise the central sensitization 
observed in migraine [15]. In rats BDNF is also co-expressed in TGNs with calcitonin gene-related 
polypeptide alpha (CGRP-), a key vasodilating neuropeptide implicated in migraine; CGRP- 
enhances the release of BDNF from TGNs, which can be abolished by a CGRP antagonist [16]. Finally, 
BDNF was one of the genes found to be differentially expressed after cortical spreading depression 
(CSD) in the rat cortex [17]. Cortical spreading depression is a slowly propagating wave of neuronal 
and glial depolarisation which can activate trigeminal nociceptors, and is thought to underlie the aura 
component of MA [18, 19].  
. 
 
Variants in BDNF have been implicated in the susceptibility to memory and hippocampal function 
impairments [20, 21], and a number of psychiatric disorders including obsessive-compulsive disorder, 
eating disorders, bipolar disorder, schizophrenia, major depression, and Alzheimer disease [22-24]. 
BDNF mutations and DNA variants have also been implicated in obesity and body mass index [25-28]. 
The most extensively studied variant is rs6265, the G196A single nucleotide polymorphism (SNP) 
which is in the proprotein region of BDNF resulting in the substitution of a valine for a methionine 
residue at position 66 (Val66Met). The polymorphism modifies the intracellular packaging of proBDNF 
and impacts on activity-dependent secretion of mature BDNF [29]. To date two studies have 
investigated whether SNPs at the BDNF locus are associated with migraine. In a case-control study on 
a German cohort, no association was found for the rs6265 SNP with migraine overall, or either the MA 
and MO subtypes [30]. Lemos et al. (2010) investigated a number of SNPs, including rs6265, at the 
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BDNF locus in a Spanish population; while they found no significant main effects they did detect an 
increased risk between the AT-genotype of rs2049046 in BDNF and the GC-genotype of rs1553005 in 
the CGRP gene, suggesting an interaction between these genes [31]. 
 
Because of the relationship between BDNF and CSD we hypothesised that polymorphisms in this gene 
may increase risk of migraine, particularly the MA subtype. Therefore in this study we investigated a 
range of SNPs in BDNF in an Australian migraine case-control population recruited from South-East 
Queensland which has a particularly large component of MA cases.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
METHODS 
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Subjects 
Two independent cohorts were used in this study. Cohort 1 consists of 277 migraineurs and 277 
controls matched for sex, age (+/-5 years) and ethnicity, recruited from in and around South Eastern 
Australia was used for this study [32]. Cohort 2 consists of 580 migraineurs and 580 sex-, age and 
ethnicity-matched controls from South-Eastern Australia. All individuals provided informed consent 
and were adult Caucasians of European decent living in Australia, having ancestors who emigrated 
within the last 160 years from various locations within the British Isles and other parts of Europe. 
Migraineurs were diagnosed by a clinical neurologist as having either MA or MO based strictly on the 
widely accepted criteria specified by the IHS [2]. The study was approved by the Griffith University, 
and subsequently the Queensland University of Technology, Ethics Committees for Experimentation 
on Human Subjects. A whole blood sample was collected from each participant and genomic DNA was 
extracted from white blood cells using a standard salting out method [33]. Samples used for the 
genotyping study were all from unrelated individuals and the control group consisted of individuals 
with no family history of migraine. 
 
Genetic Analysis 
Genotypes for rs6265 and rs2049046 were determined by restriction-fragment length polymorphism 
(RFLP) analysis of restriction enzyme-digested PCR products on 3% agarose gels. A 20-l PCR reaction 
mix contained 1xPCR buffer, 1.75 mM MgCl2, 0.2 mM dNTPs, 0.15 M of each primer, 20-40 ng of 
genomic DNA and 1.5U of GoTaq® (Promega). Thermocycler conditions were an initial denaturation 
at 95°C for 10 min, followed by 35 cycles of 95°C for 45 s, 60°C for 45s, 72°C for 45 s and a final 
extension step of 72°C for 7 min. Specific primers were used to amplify each region containing the 
SNPs and restriction enzymes (NEB) were chosen that would differentiate the two alleles after 
separation on 3% agarose gels as follows: 
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rs6265 was genotyped as described previously [34] using the primers 5’- 
CCTACAGTTCCACCAGGTGAGAAGAGT and 5’- GCTGCCGTTACCCACTCACT to generate a 480-bp PCR 
product which with AflIII is digested into four fragments of 220-, 93-, 90- and 70-bp in the case of the 
wild type “G” allele and only three fragments of 293-, 93- and 90-bp in the case of the “A” mutant 
allele. 
rs2049046 was genotyped using the primers 5’- ACCAATTTGTGCAGACCTTAAAA and 5’- 
TCAAACCCCTTTGAGATTACAGA to generate a 353-bp PCR product which with HinfI is digested into 
three fragments of 206-, 82- and 65-bp in the case of the wild type “T” allele and only two fragments 
of 271- and 82-bp in the case of the mutant “A” allele. 
Genotypes for rs1519480, rs7127507 and rs12273363 were genotyped on the Sequenom 
MassARRAY® platform with the following primers: 
5’ ACGTTGGATGCTGAAGAGTAAGAACAGATGC and 5’ ACGTTGGATGCTTAGGGAAATAAATGGAAGG and 
extension primer 5’ TTTTTTCCTTAATGGCCC for rs1519480 
5’ ACGTTGGATGTTAAAACATTCAAGCTTCC and 5’ ACGTTGGATGGAGAGAATAGAGAGTTGCGG and 
extension primer 5’ TTCAAGCTTCCTTTCTACAA for rs7127507 
5’ ACGTTGGATGGCTATTGACTGCAGGGATGA and 5’ ACGTTGGATGGCTGGGTGGTCTGAAACTTA and 
extension primer 5’ CGATGCTGCAGAAGA for rs12273363 
 
Statistical Analysis 
Hardy-Weinberg equilibrium was verified for observed genotype frequencies for each SNP to detect 
deviation from the normal genotype distribution in the population. Chi-square (χ2) analysis was 
performed to test for significant differences in genotype and allele frequencies for each SNP in 
migraineurs, MA and MO subgroups versus controls to detect any association with migraine. The 
Statistical Package for Social Sciences (SPSS version 21.0) was used for statistical analyses. Haploview 
was used to determine linkage disequilibrium in the BDNF locus. 
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RESULTS 
 
BDNF is a complex locus on chromosome 11 which generates at least 17 alternatively spliced 
transcripts and multiple alternatively spliced antisense transcripts (BDNF-AS) from the opposite 
direction [7]. Initially five SNPs, covering 39 kb of the BDNF locus were genotyped in a migraine case-
control population. Figure 1A shows the location of the SNPs with respect to a subset of BDNF 
transcripts and the haploblock structure of the locus determined and visualised from HapMap data 
using the genetic analysis program Haploview. In this study cohort 1 included 277 migraineurs, of 
which 172 were diagnosed with MA and 105 with MO, and 277 matched controls. All five SNPs that 
were genotyped were found to be in Hardy-Weinberg (p>0.05, data not shown). Our data is similar to 
the Hapmap data which shows high linkage disequilibrium (LD) throughout the locus, with SNPs 
covering the gene in a single block, although there is slightly different block definition for SNPs 5’ and 
3’ to the locus (Figure 1B). 
 
In Cohort 1 four of the SNPs (rs1519480, rs6265, rs7127507 and rs12273363) did not show any 
association with migraine. When subgroup analysis was performed for these SNPs no associations 
were detected with either MO or MA, although for rs6265 the numbers of individuals with the AA 
genotype were too few (i.e. <5) in the MO or MA subgroups to perform chi-squared analysis and 
similarly for the rs12273363 CC genotype in the MO group (Table 1). However, for rs2049046 some 
significant differences in frequencies were detected between controls and migraineurs. For total 
migraine, although the percentage of individuals with each genotype differed somewhat from the 
control group, the p-value obtained from chi-squared analysis was not significant. However, when the 
allele frequencies were compared there was a significant difference between control and migraine 
groups with an increase in frequency of the minor T-allele in migraineurs (p=0.035).  Subgroup analysis 
showed that while there was an increase in both TT genotype and T-allele frequency for MO 
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individuals compared to controls, this was not significant. However, for MA, significant differences in 
both genotype and allele frequencies were observed compared to controls (p=0.036 and p=0.0125, 
respectively). 
 
Cohort 2 was a migraine case-control population consisting of 580 migraineurs, including 107 
individuals diagnosed with MO and 473 diagnosed with MA and 580 matched controls. This cohort 
was used to investigate whether the positive association of migraine and, in particular, MA with the 
T-allele of the BDNF rs2049046 SNP could be replicated in an independent, and larger, population.  
BDNF rs6265 and rs12273363 were also genotyped in cohort 2 as they have low minor allele 
frequencies, which meant that a valid chi-squared analysis was not able to be performed in Cohort 1 
for some of the subgroups. In cohort 2, genotypic and allelic frequencies for rs6265 and rs12273363 
were not significantly different between controls and individuals with migraine or those that suffer 
from MA. Similarly for those individuals with MO, no association was found with the rs6265 A-allele. 
For the BDNF rs2049046, an increase in the frequency of the TT genotype and T-allele in migraineurs 
was detected compared to controls, similar to what was observed in Cohort 1. However, the increase 
was smaller and was not significant in either total migraine, or the MA and MO subgroups. Hence the 
interesting results from cohort 1 for this marker were not replicated in cohort 2. 
Analysis of the data from Cohorts 1 and 2 (Table 3) together also supports the conclusion that there is 
no association of BDNF rs6265 and rs12273363 with MA and/or MO. For rs2049046 the increase in 
frequency of the TT genotype or T-allele for the combined cohort 1 and 2 migraine or MA cases 
compared to controls shows significance. 
 
 
 
DISCUSSION 
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BDNF has an important role in a number of aspects of neuronal development and synaptic function 
and variants in BDNF have been associated with a wide array of diseases and conditions reflecting its 
involvement in neuronal function. Because of the correlation of BDNF levels with a number of aspects 
related to migraine studies have previously investigated some BDNF SNPs in relation to migraine risk.  
We find no association of migraine with the SNPs rs151948, rs7127507 and rs12273363, which had 
not been tested with respect to migraine previously, but had shown positive associations with other 
neurological conditions, such as bipolar and mood disorders [35, 36]. We also investigated two SNPs 
(rs6265 and rs2049046) that have been tested previously in other migraine populations, however, in 
this study, we have used a larger population which increases power, reducing the likelihood of false 
negatives, and we also have a greater proportion of migraineurs with a MA diagnosis compared to 
MO, increasing the likelihood of detecting an effect in this migraine sub-type, which we hypothesized 
BDNF may be more relevant to. Similar to the studies by Marziniak et al. (2008) and Lemos et al. (2010) 
we find no evidence of the functional BDNF SNP rs6265 as a risk factor for migraine, nor the migraine 
subtypes MO and MA. Although rs6265 is the most extensively studied SNP in the BDNF locus because 
it results in a Val to Met amino acid change that is known to affect function of the protein, we did not 
find that an increased prevalence of the Met/Met genotype or Met allele in our migraine population 
and more specifically in MA cases, which is consistent with other studies with a larger MO component. 
The rs6265 SNP is within the pro-protein region of BDNF and affects the level of mature protein [29], 
so the fact that there is no association of this SNP with migraine suggests that reduced BDNF protein 
levels in the brain do not increase the likelihood of migraine. The rs7127507 and rs12273363 SNPs 
have also been shown to influence pro-BDNF protein levels; the minor allele in each case has been 
shown to be associated with a decrease of pro-BDNF density in the hippocampus in post-mortem 
brains [37]. rs12273363 resides in promoter IV, which directs transcription of the most 5’ transcripts 
in the hippocampus, cortex and amygdala, modulating its activity in an allele-specific manner [35].  
We initially detected a significant difference in genotype and allele frequencies for the rs2049046 SNP 
in MA cases in our first cohort. However, in a second larger cohort, although we still observed a 
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decrease in the percentage of individuals with the rs2049046 AA-genotype and an increase in those 
with the TT-genotype in migraineurs, this was not significant for either total migraine or with respect 
to the MO or MA sub-groups. Lemos et al. (2010) had found an increased risk of migraine associated 
with the heterozygous AT genotype at rs2049046, but only in association with the heterozygous 
genotype the calcitonin gene-related peptide SNP rs1553005 [31]. The rs2049046 SNP is located at 
the 5’ end of the BDNF locus, in promoter III upstream of some of the alternative transcription start 
sites of the gene and a region that also contains SNPs that have been identified from genome wide 
association studies for obesity [26]. It has been shown that with respect to obesity, it is the absence 
of a specific transcript of BDNF with a long 3’UTR that is causal rather than the level of BDNF mRNA in 
a mouse obesity syndrome model [38]. Conceivably, similar to rs7127507 and rs12273363, SNPs in the 
5’ end of the locus may also influence tissue-specific transcription or levels of particular BDNF 
transcripts for obesity, as well as any other conditions that show associations.  
In the population studied here we found high LD (calculated by D’) throughout the BDNF locus with 
most of the gene encompassed in a single block (Fig. 1b). This agrees with data from Hapmap (Fig. 1a) 
and other BDNF SNP association studies of populations with conditions such as bipolar disorder, opoid 
addiction and Alzheimer’s disease [21, 23, 36]. These data sets all found high LD across the locus, but 
fine mapping revealed a few interspersed local regions of lower LD with independent SNPs. This may 
reflect the important function of the gene in many aspects of brain function as well as the complicated 
regulatory landscape of the locus. Minor allele frequencies were similar to those reported for the CEU 
population in HapMap. However, the allelic frequencies for all the BDNF SNPs investigated in this study 
appear to vary greatly between the different Hapmap populations, so conclusions from one 
population may not apply in another population and care would need to be taken that ethnicity is 
taken into account. 
It should be noted that SNPs at the BDNF locus have not reached genome-wide significance in the 
genome-wide association studies that have been performed for common migraine (which included 
analysis of MA and MO sub-groups) or specifically MO [39, 40]. However, with the sample sizes used 
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to date only a small number of genes have been found to be robustly implicated in migraine [41]. In 
conclusion, we found that rs2049046, which resides at the 5’ end of one the BDNF transcripts, to be 
significantly associated with migraine, and in particular MA, in an Australian migraine case-control 
population. While a second cohort showed a similar trend, the results were not significant. Thus while 
there is no conclusive evidence to implicate the BDNF rs2049046 genotype in migraine susceptibility, 
larger studies may help to either rule it in or out if the effect size is low. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure legends. 
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Figure 1. Gene transcription, SNP location and haploblock structure of the BDNF locus. A. Schematic 
of the the SNPs genotyped in this study in relationship to the BDNF gene and some of its transcripts, 
and linkage disequilibrium (LD) values between SNPs from Hapmap data at the locus. Top panel: SNPs 
genotyped in this study are boxed in yellow with arrows pointing to position along the BDNF locus. 
BDNF isoforms are transcribed from the reverse strand (direction indicated by dashed arrow) and a 
subset are depicted to indicate the main regions of initiation (see [7] for a full description, including 
antisense transcripts). Black boxes represent the protein coding sequence, while dark grey boxes 
represent untranslated exons. Bottom panel: Hapmap data was used to generate the LD values 
(calculated by D’) for multiple SNPs across the BDNF locus from rs1519480 (chr11:27675462) to 
rs2049048 (chr11:27750836) in Haploview, including rs1519480, rs6265, rs712507 and rs12273363. 
rs2049046 was not available in Hapmap.. Darker squares indicated higher LD; dark red squares 
indicate SNPs are in complete LD (100% or D’ =1), and numbers in lighter squares are the percentage 
when LD is incomplete. B. LD values generated from the BDNF SNPs genotyped in Cohort 1 from this 
study, including rs2049046. 
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Table 1 . Genotype and allele frequencies for BDNF SNPs in migraine case-control cohort 1 
SNP Group Genotypes P Alleles  P 
rs1519480  TT (%) TC (%) CC (%)  T (%) C (%)  
Control 121  
(51.3) 
94  
(39.8) 
21  
(8.9) 
- 336  
(71.2) 
136  
(28.8) 
- 
Migraine 115  
(48.7) 
96  
(40.7) 
25  
(10.6) 
0.771 326  
(69.1) 
146  
(30.9) 
0.755 
MO 50  
(55.6) 
34  
(37.8) 
6  
(6.7) 
0.708 134 
(74.4) 
46  
(25.6) 
0.407 
MA 65  
(44.5) 
62  
(42.5) 
19  
(13.0) 
0.293 192  
(65.8) 
100  
(34.2) 
0.114 
         
rs6265  GG (%) GA (%) AA (%)  G (%) A (%)  
Control 171  
(69.5) 
68  
(27.6) 
7  
(2.8) 
- 410  
(83.3) 
82  
(16.7) 
- 
Migraine 131  
(65.2) 
64  
(31.8) 
6  
(3.0) 
0.614 326  
(81.1) 
76  
(18.9) 
0.383 
MO 49 
 (70.0) 
19 
(27.1) 
2 
(2.9) 
NC 117  
(83.6) 
23  
(16.4) 
0.947 
MA 82  
(62.6) 
45  
(34.4) 
4 
(3.1) 
NC 209 
(79.8) 
53 
(20.2) 
0.224 
         
rs7127507  TT (%) TC (%) CC (%)  T (%) C (%)  
Control 114 
(46.2) 
113 
(45.7) 
20 
(8.1) 
- 341  
(69.0) 
153  
(31.0) 
- 
Migraine 114  
(46.3) 
108  
(43.9) 
24  
(9.8) 
0.789 336 
(68.3) 
156 
(31.7) 
0.803 
MO 49  
(51.6) 
39  
(41.1) 
7  
(7.4) 
0.667 137  
(72.1) 
53  
(27.9) 
0.432 
MA 65 
(43.0) 
69 
(45.7) 
17 
(11.3) 
0.546 199  
(65.9) 
103  
(34.2) 
0.358 
         
rs2049046  AA (%) AT (%) TT (%)  A (%) T (%)  
Control 60  
(24.6) 
128  
(52.5) 
56  
(23.0) 
- 248  
(50.8) 
240  
(49.2) 
- 
Migraine 46 
(19.6) 
115  
(48.9) 
74  
(31.5) 
0.088 207 
(44.0) 
263  
(56.0) 
  0.035* 
MO 23  
(27.1) 
36  
(42.4) 
26  
(32.0) 
0.232 82  
(48.2) 
88  
(51.8) 
0.562 
MA 23  
(15.3) 
79  
(52.7) 
48  
(29.0) 
0.036* 125  
(41.7) 
175  
(58.3) 
0.0125* 
         
rs12273363  TT (%) TC (%) CC (%)  T (%) C (%)  
Control 167 
(66.0) 
74 
(29.2) 
 12  
(4.7) 
- 408 
(80.6) 
98 
(19.4) 
- 
Migraine 160  
(64.5) 
79  
(31.9) 
9  
(3.6) 
0.708 339 
(68.3) 
97 
(19.6) 
0.940 
MO 70  
(72.9) 
25  
(26.0) 
1  
(1.0) 
NC 165 
(85.9) 
27 
(14.1) 
0.103 
22 
 
MA 90 
(59.2) 
54 
(35.5) 
8 
(5.3) 
0.382 234 
(77.0) 
70 
(23.0) 
0.214 
P-values were calculated by χ2-analysis, significance was taken at P≤0.05 (*). 
NC p-value not calculated as minimum number for each category needs to be >5 for χ2-squared 
analysis. 
MO- Migraine without aura, MA- Migraine with aura 
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Table 2. Genotype and allele frequencies for BDNF SNPs in migraine case-control cohort 2 
SNP Group Genotypes P Alleles  P 
rs6265  GG (%) GA (%) AA (%)  G (%) A (%)  
Control 373 
(68.3) 
156 
(28.6) 
17 
(3.1) 
- 902  
(82.6) 
190  
(17.4) 
- 
Migraine  265 
(64.5) 
129  
(31.4) 
17 
(4.1) 
0.400 659  
(80.2) 
163  
(19.8) 
0.175 
MO 46 
(62.2) 
25 
(33.8) 
3* 
(4.1) 
0.563 117  
(79.1) 
31  
(20.9) 
0.290 
MA 229 
(66.0) 
104 
(30.0) 
14 
(4.0) 
0.660 562 
(81.0) 
132 
(19.0) 
0.385 
         
rs2049046  AA (%) AT (%) TT (%)  A (%) T (%)  
Control 135 
(24.1) 
280 
(49.9) 
146 
(26.0) 
- 550  
(49.0) 
572  
(51.0) 
- 
Migraine 111 
(20.2) 
279 
(50.8) 
159 
(29.0) 
0.251 501  
(45.6) 
597  
(54.4) 
0.110 
MO 21 
(21.2) 
45 
(45.5) 
33 
(33.3) 
0.319 87 
(43.9) 
111 
(56.1) 
0.187 
MA 90 
(20.0) 
234 
(52.0) 
126 
(28.0) 
0.297 414 
(46.0) 
486 
(54.0) 
0.177 
         
rs12273363  TT (%) TC (%) CC (%)  T (%) C (%)  
Control 371 
(66.4) 
162 
(29.0) 
26 
(4.6) 
- 904  
(80.9) 
214  
(19.1) 
- 
Migraine 332 
(64.1) 
168 
(32.4) 
18 
(3.5) 
0.338 832  
(80.3) 
204  
(19.7) 
0.747 
MO 56 
(60.2) 
31 
(33.3) 
6 
(6.5) 
0.473 143 
(76.9) 
43 
(23.1) 
0.207 
MA 276 
(63.5) 
137 
(32.2) 
12 
(2.8) 
0.223 689 
(81.1) 
161 
(18.9) 
0.911 
P-values were calculated by χ2-analysis, significance was taken at P≤0.05 (*). 
NC p-value not calculated as minimum number for each category needs to be >5 for χ2-squared 
analysis. 
MO- Migraine without aura, MA- Migraine with aura 
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Table 3. Genotype and allele frequencies for BDNF SNPs in migraine case-control population of 
cohorts 1 and 2 combined. 
SNP Group Genotypes P Alleles  P 
rs6265  GG (%) GA (%) AA (%)  G (%) A (%)  
Control 544  
(68.7) 
224  
(28.3) 
24  
(3.0) 
- 1312 
(82.8) 
272  
(17.2) 
- 
Migraine 396  
(64.7) 
193  
(31.5) 
23  
(3.8) 
0.273 985  
(80.5) 
239  
(19.5) 
0.109 
MO 95  
(66.0) 
44  
(30.5) 
5  
(3.5) 
0.807 234  
(81.3) 
54  
(18.7) 
0.516 
MA 311  
(65.0) 
149  
(31.2) 
18  
(3.8) 
0.384 771  
(80.6) 
185  
(19.4) 
0.166 
rs2049046  AA (%) AT (%) TT (%)  A (%) T (%)  
Control 195  
(24.2) 
408  
(50.7) 
202  
(25.1) 
- 798  
(49.6) 
812  
(50.4) 
- 
Migraine 157  
(20.0) 
394  
(50.3) 
233  
(29.7) 
0.043* 708  
(45.1) 
860  
(54.9) 
0.013* 
MO 44  
(23.9) 
81  
(44.0) 
59  
(32.0) 
0.128 169  
(45.9) 
199  
(54.1) 
0.207 
MA 113  
(18.8) 
313  
(52.2) 
174  
(29.0) 
0.036* 539  
(44.9) 
661  
(55.1) 
0.015* 
rs12273363  TT (%) TC (%) CC (%)  T (%) C (%)  
Control 538  
(66.3) 
236  
(29.0) 
38  
(4.7) 
- 1312  
(80.8) 
312  
(19.2) 
- 
Migraine 492  
(64.2) 
247  
(32.2) 
27  
(3.6) 
0.243 1231  
(80.4) 
301  
(19.6) 
0.757 
MO 126  
(66.7) 
56  
(29.6) 
7  
(3.7) 
0.841 308  
(81.5) 
70  
(18.5) 
0.757 
MA 366  
(63.4) 
191  
(33.1) 
20  
(3.5) 
0.183 923  
(80.0) 
231  
(20.0) 
0.598 
P-values were calculated by χ2-analysis, significance was taken at P≤0.05 (*). 
MO- Migraine without aura, MA- Migraine with aura 
 
 
 
